hema.to

Diseases & Conditions Cancer
Technologies Artificial Intelligence
Funding π°
Total β¬3.6M
Select investors Heal Capital, High-Tech Grunderfonds (HTGF), Elaia
Key people π§βπ€βπ§
- Dr. Karsten Miermans - Co-founder & CEO
- Felix Kunzweiler - Co-founder & CTO
- Dr. Franz Elsner - Co-founder & Chief Research Officer
- Dr. Hannes LΓΌling - Co-founder & MD
Highlights β
- Solving the problem: Cytometry, the clinical analysis of blood data, is a time-consuming exercise, coupled with shortages in laboratory staff, there was much scope for the system to be improved upon. hema.to wants to improve the system by using its cloud-based machine learning platform to personalize the analysis and bring "precision diagnostics to immune medicine."
- Scientifically backed: In a series of papers, the company has demonstrated that its core AI algorithms are capable of hematologist-level B-NHL classifications and that this knowledge can be transferred across different flow protocols. π
- Demonstrated quality: Medical software requires development processes that meet the highest standards. hema.to is a CE-IVD product and is scientifically backed by peer-reviewed publications.
- Key numbers: hema.to supports over 5k diagnoses, offering 99.7% accuracy for strong infiltration cases. Also, more than 75% of cases potentially don't require human intervention.
Video βΆοΈ
Awards & Recognitions π
- 2022 Medical Valley Innovation Night: First prize π
Quotes π¬
“
We have been convinced by the founding team, composed of three former entrepreneurs from the same company, with three PhD profiles, at a stage where they are going to scale their go to market, which is coherent with our deep tech seed investment thesis. I rejoice because hema.to is Elaia's first investment in Germany.
— Anne-Sophie Carrese, Managing Partner at Elaia Partners π
Last update: July 11, 2023
Disclaimer: We can not guarantee that the information on this page is 100% correct. more